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Abstract
Objective. To present the usefulness of a centralized system of data collection for the development of an
international multicentre registry of SpA.
Method. The originality of this registry consists in the creation of a virtual network of researchers in a
computerized Internet database. From its conception, the registry was meant to be a dynamic acquiring
system.
Results. REGISPONSER has two developing phases (Conception and Universalization) and gathers sev-
eral evolving secondary projects (REGISPONSER-EARLY, REGISPONSER-AS, ESPERANZA and
RESPONDIA). Each sub-project answered the necessity of having more specific and complete data of
the patients even from the onset of the disease so, in the end, obtaining a well-defined picture of SpAs
spectrum in the Spanish population.
Conclusion. REGISPONSER is the first dynamic SpA database composed of cohorts with a significant
number of patients distributed by specific diagnosis, which provides basic specific information of the sub-
cohorts useful for patients’ evaluation in rheumatology ambulatory consulting.
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Introduction
Health-care managers need reliable instruments to help
them distribute and allocate health and social resources
objectively and fairly. These instruments should be
flexible and provide real-time data, and they should
easily incorporate any change in practice and scientific
knowledge. Disease registries are most suitable for this
task, as they provide real-time data on the frequency,
geographic and temporary distribution, as well as on the
pattern of the disease [1]. They inform about the case mix
in different locations and provide an enlightening tool for
assessing the impact of the disease and clinical practice
variability. Furthermore, disease registries are an ideal
source of random samples for cohort studies or for
case–control studies, the correct setting to test medical
hypothesis [2]. Our experience from the registries de-
veloped over the past few years has shown us their use-
fulness in describing the epidemiological aspects, clinical
pattern, disease activity, structural damage, response to
therapy, impairment degree in quality of life and
socio-economic impact associated with inflammatory
rheumatic diseases, in our case focused on patients
with SpAs.
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was initiated in April 2004, by SpAs study group of the
Spanish Society of Rheumatology (GRESSER). Thereby,
REGISPONSER (Registro Espan ˜ol de Espondiloartritis
de la Sociedad Espan ˜ola de Reumatologia), that is, The
Spanish National Registry of SpAs, is composed of a large
enough cohort of patients to enable us to determine a
well-defined picture of patient characteristics and the pro-
gress of their diseases, even from onset.
Methods
The originality of this registry has been the creation of a
virtual network of researchers set upon a computerized
Internet database accessible to all participating members,
irrespective of which city or country they belong to (http://
regisponser.ser.es/). Each centre has individual access to
the registry, either for investigation or for managing
purposes. The online application is easily accessible via
a standard Internet browser. No additional software is
needed to be installed on the user’s computer. Once the
self-administered patients’ validated questionnaires are
achieved, the data are introduced in the electronic clinical
research form (e-CRF), under strict quality control by fil-
ters that detect data inconsistencies, for assuring the uni-
formity of data collection. The information contained in
these e-CRFs was agreed with all the investigators
before starting the database. The e-CRF provides the
basic minimum data set required for the complete defin-
ition of the patient and his illness, according to the rec-
ommendations of ASAS (Assessment of Ankylosing
Spondylitis International Society) [3] (Table 1). A specific
code (login and password) is assigned to each investiga-
tor to access the e-CRF and random codes are given to
each introduced case. In this way, the system meets the
rules of the protection of personal data. The system per-
forms an automatic log out after a predefined period of the
user’s inactivity. This function prevents abuse of the
system if the user forgets to log off. All submitted data
are encrypted and collected in a central computer,
where they are safely stored in the database. The data
can be exported for authorized users as a local database
for further processing. This study was approved by the
Committee of Ethical and Sanitary Investigation of Reina
Sofia University Hospital. Each patient has signed an in-
formed consent at inclusion in REGISPONSER, according
to the fundamental principles established in the
Declaration of Human Rights in Helsinki.
Results
Phase I
At its first beginning (2004–05) the registry (REGISPONSER I)
was comprised of 12 reference Spanish rheumatology de-
partments selected from all the centres that agreed to
participate in the project, based on their experience in
treating SpA patients. These centres, from eight different
cities, represent a broad socio-demographic spectrum of
the population attended at the Spanish Health System.
The average population covered by the participating hos-
pitals is 800000 (range 300000–1100000), and includes
urban and rural zones. The participating rheumatologists
were asked to include all consecutive patients fulfilling the
inclusion criteria up to a minimum of 100 per centre.
The main purposes of REGISPONSER I were to create,
develop and exploit the Spanish national registry of pa-
tients with SpA and its specific objective was to determine
the characteristics of the Spanish patients with SpA
(socio-demographic, clinical, radiological, laboratory and
treatment features) in a cross-sectional study (photog-
raphy). REGISPONSER I included 1379 patients fulfilling
European Spondyloarthropathy Study Group (ESSG) clas-
sification criteria and the results were already published
[4]. The results of this project were: (i) development of a
useful computer application; (ii) user-friendly patient data
processing obtained from different centres; and (iii) direct
information of the characteristics of the Spanish SpA pa-
tients, although the most important goal achieved by
REGISPONSER I has been the growing interest of the
Spanish rheumatologists in SpA and so, thereby ‘in-
creasing the visibility of SpA in Spain’.
Phase II
After the data-acquiring system was validated, an invita-
tion was sent to all those Spanish rheumatology centres
that met the minimum requirement criteria, and hence
other 19 centres joined the project. Thus, by the end of
March 2007, 2367 patients were included in the registry.
This phase of the project is known as Universalization.
REGISPONSER II helped to increase knowledge of SpAs
in the Spanish population and to incite the development of
new projects. REGISPONSER II collected information
from 31 Spanish rheumatologic departments, from 31 dif-
ferent hospitals belonging to 19 provinces that cover a
wide spectrum of the Spanish habitants with different
social, economic and occupational conditions.
Continuous development
REGISPONSER II is a dynamic project that collects stan-
dardized socio-demographic, clinical, biological, radio-
logical, genetic and treatment data relevant to SpAs
spectrum. The authenticity of this project consists in the
requirement that all the patients included to fulfil both
ESSG and Amor criteria for SpA. Several studies were
developed from REGISPONSER II and the results have
already been published [5–7]. In addition to these pub-
lished results, REGISPOSER II revealed some interesting
facts: first, by increasing the sample, clinical and demo-
graphic outcomes obtained in REGISPONSER I did not
change significantly [8]; and secondly, there was an un-
acceptable delay of 8.6 years in SpA diagnosis in Spain.
Therefore, we created an ambitious project that involves
both general practitioners and rheumatologists called
ESPERANZA, with the purpose of early detection of SpA.
The goals were to create and establish units for the
early management of patients with SpAs and to develop
a communication system between general practitioners
www.rheumatology.oxfordjournals.org 133
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Ruxandra Schiotis etal.and rheumatologists for early referral of patients with sus-
pected spondylitis, according to the following criteria: pa-
tients <45 years of age with >3 and <24 months of
evolution of one of the three following syndromes:
(i) inflammatory back pain, defined in the specific case
of the project as back pain with at least two out of three
from the following: insidious onset, morning stiffness >30
min and improvement with exercise; (ii) asymmetrical oli-
goarthritis of the lower limbs (at least one and maximum
four big joints in the lower limbs affected asymmetrically);
and (iii) other suspicious criteria as: rachialgia plus at least
one of following: psoriasis; IBD; acute anterior uveitis;
family history of SpA, psoriasis, IBD or anterior uveitis;
Rx sacroiliitis; and HLA-B27 positivity. At present there
are 25 rheumatologic centres and 2099 general practition-
ers involved in the programme that has derived 898 new
patients. Parts of the results have been reported during
the 2009 EULAR Congress [9].
The main advantage of REGISPONSER II is that it pro-
vides a source of well-characterized patients treated in
Spanish rheumatology centres, which may be used as
database for new prospective projects (Fig. 1). Thus, a
number of such new prospective secondary projects are
now in progress: (i) REGISPONSER-EARLY that is com-
prised of a cohort of patients with SpAs with <5 years
of disease evolution (150 patients) [10]; and (ii)
REGISPONSER-AS, designed for the cohort of patients
with AS, which contains 529 patients. In this cohort, we
are also evaluating some of the most important genetic
biomarkers known to be related with the disease suscep-
tibility and pathogenesis. For these two sub-projects,
screens and appropriate collection filters to alert that a
specific patient was selected were created. A system for
tracking and monitoring the patients was established. It
was required that each selected patient fulfilled five visits
(one every year). For the statistical analysis, statistical
programs and SPSS (SPSS PASW Statistics v.18 spanish
version, Chicago, IL) are used. The analysis plan varies,
depending on the sub-studies.
Furthermore, due to our collaboration with the Latin
American countries interested in SpAs, we also started
a sub-project in which 10 Latin American countries
(Argentina, Brazil, Costa Rica, Chile, Mexico, Peru,
Uruguay and Venezuela) and over 100 rheumatologists
were included. They were accepted initially to use the
electronic platform of REGISPONSER II for introducing
the same standardized data following the Spanish proto-
col. In this way, during 2005–06 RESPONDIA was formed
as part of REGISPONSER.
RESPONDIA is now an independent project, gathering
almost 2000 patients fulfilling the ESSG criteria of SpAs
and has its own general coordinator. Results from this
registry were published [11], and, moreover, the epidemi-
ology and risk factors associated with hip involvement in
AS [12] were confirmed.
Discussions
REGISPONSER is an ambitious programme that currently
involves, as a whole, more than 500 Spanish-speaking
rheumatologists (and Portuguese) and contains data
from more than 6000 SpAs patients. One of the most im-
portant achievements was the incorporation of a self-
administered questionnaire into daily clinical practice
leading to a uniformity of data collection that further
enable the comparison and analysis of data obtained
from different sources [3]. REGISPONSER is providing
rheumatologists, on one hand, demographic, socio-
economic and clinical data and, on the other, information
about evolution of the disease in each patient by means
of clinical, biological and radiographic assessments. The
efficiency of the treatment administrated to the patients
FIG.1Evolution of REGISPONSER registry.
REGISPONSER I
12 centres
1379 patients
REGISPONSER II
Universalization (until March
2007)
31 centres
2367 patients
￿ prevalence of fibromyalgia on SpA
   patients  
￿ work disability in AS patients
￿ relationship between spinal mobility
  and disease activity, function, quality
  of life and radiology   
  ￿ hip epidemiology in SpA 
RESPONDIA
Iberoamerica registry of SpA:
10 countries
60 centres
2044 patients
REGISPONSER-AS
31 centres
529 AS patients
REGISPONSER-EARLY
31 centres
261 SpA patients (<5 years 
from the onset)
ESPERANZA
25 rheumatologic centres
2099 general practitioners
898 derived patients
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Usefulness of a centralized system of data collectioncan also be evaluated, as can the implication of genetic
factors in disease evolution and in response to different
therapies. Furthermore, implementation of this project has
helped raise the profile of SpA, by increasing the knowl-
edge and interest of the participating rheumatologists in
these interesting conditions.
Conclusion
REGISPONSER is the first dynamic SpA database com-
posed of cohorts with a significant number of patients
distributed by specific diagnosis, which provides basic
specific information of the sub-cohorts useful for patients’
evaluation in rheumatology ambulatory consulting.
Rheumatology key messages
. REGISPONSER increased awareness of SpAs.
. REGISPONSER provides a characterization of the
Spanish SpA patients, useful for their evaluation in
ambulatory consulting.
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